

Wright Medical Group N.V.
Supplemental Net Sales Information
(unaudited)

Three months ended March 26, 2017 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	0%	(8%)	(12%)	(2%)	(2%)
Upper extremities	12%	10%	7%	11%	10%
Biologics	9%	24%	23%	12%	12%
Sports med & other	(2%)	0%	(6%)	0%	(4%)
Total net sales	6%	4%	1%	6%	5%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	
	<u>March 26, 2017</u>	<u>March 27, 2016</u>
Gross profit from continuing operations, as reported	\$ 140,065	\$ 122,625
Gross margins from continuing operations, as reported	79.0 %	72.4 %
Reconciling items impacting gross profit:		
Inventory step-up amortization	—	10,229
Transaction and transition costs	685	124
Non-GAAP gross profit from continuing operations, as adjusted	\$ 140,750	\$ 132,978
Net sales from continuing operations	177,191	169,291
Non-GAAP adjusted gross margins from continuing operations	79.4%	78.5%

Wright Medical Group N.V.

Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share

(dollars in thousands, except per share data--unaudited)

	Three months ended	
	March 26, 2017	March 27, 2016
Net loss from continuing operations, as reported	\$ (36,707)	\$ (40,193)
Net loss from continuing operations per share, as reported	\$ (0.35)	\$ (0.39)
Reconciling items:		
Inventory step-up amortization	—	10,229
Non-cash interest expense on convertible notes ¹	10,999	7,056
Derivatives mark-to-market adjustments ²	365	(6,641)
Transaction and transition costs	2,972	10,833
CVR mark-to-market adjustments ²	6,160	5,324
Tax effect of reconciling items ³	(18)	(1,189)
Non-GAAP net loss from continuing operations, as adjusted	\$ (16,229)	\$ (14,581)
Add back amortization of intangible assets	7,397	6,457
Adjusted non-GAAP earnings	\$ (8,832)	\$ (8,124)
Weighted-average basic shares outstanding	103,663	102,704
Adjusted non-GAAP earnings per share	\$ (0.09)	\$ (0.08)

¹ Impacting interest expense, net

² Impacting other expense (income), net

³ Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	
	March 26, 2017	March 27, 2016
Net loss from continuing operations	\$ (36,707)	\$ (40,193)
Interest expense, net	18,195	11,854
Provision (benefit) from income taxes	939	(1,287)
Depreciation	13,446	12,850
Amortization	7,397	6,457
Non-GAAP EBITDA	\$ 3,270	\$ (10,319)
Reconciling items impacting EBITDA:		
Non-cash share-based compensation expense	3,954	3,317
Other expense (income), net	7,975	(1,068)
Inventory step-up amortization	—	10,229
Transaction and transition costs	2,972	10,833
Non-GAAP adjusted EBITDA	\$ 18,171	\$ 12,992
Net sales from continuing operations	177,191	169,291
Non-GAAP adjusted EBITDA margin	10.3%	7.7%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results
(dollars in thousands--unaudited)

	Three months ended	
	March 26, 2017	March 27, 2016
Net sales	\$ 177,191	\$ 169,291
Selling, general and administrative expense, as reported	\$ 129,834	\$ 134,746
Selling, general and administrative expense as a percentages of net sales, as reported	73.3 %	79.6 %
Reconciling items impacting selling, general and administrative expense:		
Transaction and transition costs - selling, general and administrative	2,287	10,560
Selling, general and administrative expense, as adjusted	\$ 127,547	\$ 124,186
Selling, general and administrative expense as a percentage of net sales, as adjusted	72.0%	73.4%
Research & development expense, as reported	\$ 12,432	\$ 12,116
Research & development expense as a percentages of net sales, as reported	7.0 %	7.2 %
Reconciling items impacting research & development expense:		
Transaction and transition costs - research & development	—	149
Research & development expense, as adjusted	\$ 12,432	\$ 11,967
Research & development expense as a percentage of net sales, as adjusted	7.0%	7.1%